Corcept's Stock Surges on Ovarian Cancer Drug News

Corcept Therapeutics' stock surged nearly eight percent following its European marketing application for relacorilant, an ovarian cancer drug showing promising trial results. This spike follows a recent 12% drop triggered by a top executive's pre-planned stock sale, highlighting the stock's volatility. Despite these fluctuations, Corcept remains up over 50% year-to-date, with investors closely awaiting regulatory decisions in both Europe and the U.S.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.